
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Pediatric dermatology leaders are making strides toward giving their specialty the clout they believe it deserves. Not only has pediatric dermatology become a board certified subspecialty, but it now offers accredited and standardized one-year fellowships.